2025
A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children
McGovern S, Johnson J, Luo D, Nguyen K, McAleer M, Paulino A, Grosshans D, Baxter P, Zaky W, Thall P, Mahajan A. A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children. International Journal Of Radiation Oncology • Biology • Physics 2025, 121: e13-e14. DOI: 10.1016/j.ijrobp.2024.11.049.Peer-Reviewed Original ResearchDose-volume constraintsSymptomatic brain necrosisRecurrent brain tumorsBrain tumorsBrain necrosisPrimary endpointDose constraintsProton therapyProspective studyRecurrent pediatric brain tumorsMedian overall survivalMedian prescription doseCourse of radiationResults Median ageTreated with radiationPediatric brain tumorsPrimary brain tumorProgression of diseaseBrain reirradiationDosimetric guidelinesDose escalationPrescription doseOverall survivalMedian intervalProspective trialsLocal definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study.
Dizman N, Doshi S, Knezevic A, Feinaj A, Sayegh N, Hobeika C, Alaghehbandan R, Rives H, Zengin Z, Braun D, Zibelman M, McGregor B, Hammers H, Ged Y, Ornstein M, Msaouel P, Hahn A, Voss M. Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study. Journal Of Clinical Oncology 2025, 43: 503-503. DOI: 10.1200/jco.2025.43.5_suppl.503.Peer-Reviewed Original ResearchLocal definitive therapySarcomatoid dedifferentiationMetachronous metastasesSystemic treatmentST cohortDuration of disease controlChromophobe renal cell carcinomaTreatment characteristics of patientsMetastatic disease diagnosisSingle-organ metastasisTreatment-free intervalTreatment-free survivalKaplan-Meier methodRenal cell carcinomaFisher's exact testCharacteristics of patientsMulti-institutional studyWilcoxon rank sum testRank sum testMetastatic sitesSurgical resectionDefinitive therapyRare subtypeMedian intervalCell carcinoma
2024
Factors influencing timely diagnosis in neurolymphomatosis
Doubrovinskaia S, Egert A, Karschnia P, Scheffler G, Traub B, Galluzzo D, Huttner A, Fulbright R, Baehring J, Kaulen L. Factors influencing timely diagnosis in neurolymphomatosis. Journal Of Neuro-Oncology 2024, 170: 309-317. PMID: 39115616, DOI: 10.1007/s11060-024-04792-2.Peer-Reviewed Original ResearchNon-Hodgkin's lymphomaPeripheral nervous systemDiagnostic intervalNon-Hodgkin lymphoma diagnosisSymptom onset to diagnosisCerebrospinal fluid examinationYale Cancer CenterPainful polyneuropathyAsymmetric neuropathyRare entityMedian intervalFluid examinationQuality control databaseDelayed diagnosisPrimary diseaseUnivariate analysisConventional CTDisease sitesNeurolymphomatosisNeuro-oncologyCancer CenterSecondary diseaseImaging modalitiesNeuroimaging findingsDiagnosisCombined neuromodulation and resection for functional cortex epilepsy: a case series.
Merenzon M, Sivaraju A, Herlopian A, Gerrard J, Quraishi I, Hirsch L, Spencer D, Damisah E. Combined neuromodulation and resection for functional cortex epilepsy: a case series. Journal Of Neurosurgery 2024, 141: 1527-1535. PMID: 38848588, DOI: 10.3171/2024.3.jns24122.Peer-Reviewed Original ResearchMedically refractory epilepsySeizure onset zoneFunctional cortexSeizure outcomeRefractory epilepsyMonths of follow-up dataMaximal safe resectionMedian follow-upTreated with resectionImprove seizure outcomeFocal neuromodulationFollow-up dataPreservation of functionRetrospective analysis of individualsSafe resectionPartial resectionMedian intervalCase seriesPreoperative assessmentSurgical interventionRNS deviceNeurological deficitsNo significant changesResectionRetrospective analysisAdditive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade Gliomas
Yadav D, Upadhyay R, Kumar V, Chen M, Johnson J, Langshaw H, Curl B, Farhat M, Talpur W, Beckham T, Yeboa D, Swanson T, Ghia A, Li J, Chung C. Additive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade Gliomas. Practical Radiation Oncology 2024, 14: e449-e457. PMID: 38685448, DOI: 10.1016/j.prro.2024.04.009.Peer-Reviewed Original ResearchPseudo-progressionResponse assessmentInterobserver agreementImprove response assessmentPost-operative MRIFollow-up MRIFollow-up imagingEvaluate treatment responseHigh-grade gliomasIndependent blinded reviewIdentification of patientsClinical trial enrollmentWeeks of RTPartial response(PRStable disease(SDRT planningSalvage treatmentTumor responseEarly time pointsMedian intervalImprove patient outcomesTrue progressionProspective studyTreatment responseTumor progressionInterim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024
DeCuir J, Payne A, Self W, Rowley E, Dascomb K, DeSilva M, Irving S, Grannis S, Ong T, Klein N, Weber Z, Reese S, Ball S, Barron M, Naleway A, Dixon B, Essien I, Bride D, Natarajan K, Fireman B, Shah A, Okwuazi E, Wiegand R, Zhu Y, Lauring A, Martin E, Gaglani M, Peltan I, Brown S, Ginde A, Mohr N, Gibbs K, Hager D, Prekker M, Mohamed A, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Chang S, Mallow C, Kwon J, Exline M, Columbus C, Vaughn I, Safdar B, Mosier J, Harris E, Casey J, Chappell J, Grijalva C, Swan S, Johnson C, Lewis N, Ellington S, Adams K, Tenforde M, Paden C, Dawood F, Fleming-Dutra K, Surie D, Link-Gelles R, Collaborators C, Collaborators C, Ghamande S, Gottlieb R, McNeal T, Raver C, Bender W, Fletcher L, Heaton P, Kane S, McEvoy C, Thapa S, Vazquez-Benitez G, Frosch A, Lamerato L, Ramesh M, Arnofer J, Ali H, Hopkins J, Crane B, Dandamudi P, Goddard K, Hansen J, Timbol J, Zerbo O, Allen K, Duszynski T, Fadel W, Rogerson C, Qadir N, Chavez C, Doyle B, Mayer D, Rao S, Rivas C, Johnson N, Baughman A, Lwin C, Rhoads J, Womack K, Dunne M, Ciesla A, Mak J, Najdowski M, Ray C. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024. MMWR Morbidity And Mortality Weekly Report 2024, 73: 180-188. PMID: 38421945, PMCID: PMC10907041, DOI: 10.15585/mmwr.mm7308a5.Peer-Reviewed Original ResearchConceptsVaccine effectivenessEmergency departmentCOVID-19 vaccineCDC's Advisory CommitteeCOVID-19-associated hospitalizationUrgent careCOVID-19 vaccine dosesImmunocompetent adultsMedian intervalCase-control designVE estimatesVaccine doseImmunization PracticesTest-negativeSevere diseaseCDC recommendationsDoseVaccineHospitalVE networkCOVID-19CDCMonthsAdvisory CommitteeDays
2023
Safety and efficacy of thoracic endovascular aortic repair for acute Stanford type B aortic dissection with retrograde type A intramural hematoma
Wang J, Li M, Li J, He H, Zhou Y, Li X, Li Q, Gu F, Ye Z, Dardik A, Shu C. Safety and efficacy of thoracic endovascular aortic repair for acute Stanford type B aortic dissection with retrograde type A intramural hematoma. Journal Of Vascular Surgery 2023, 78: 61-69.e4. PMID: 36921645, DOI: 10.1016/j.jvs.2023.02.021.Peer-Reviewed Original ResearchConceptsThoracic endovascular aortic repairType B aortic dissectionAcute Stanford type B aortic dissectionStanford type B aortic dissectionB aortic dissectionEndovascular aortic repairHematoma thicknessAortic dissectionRetrograde typeIntramural hematomaAortic repairMaximal diameterAcute type B aortic dissectionOverall cumulative survival rateCumulative survival rateCumulative freedomAortic remodelingComplication rateEndovascular repairMedian intervalPatient characteristicsSymptom onsetAortic diameterAlternative treatmentPatients
2022
P11.54.A Factors effecting early diagnosis in neurolymphomatosis
Egert A, Karschnia P, Huttner A, Baehring J, Kaulen L. P11.54.A Factors effecting early diagnosis in neurolymphomatosis. Neuro-Oncology 2022, 24: ii70-ii70. PMCID: PMC9443184, DOI: 10.1093/neuonc/noac174.243.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaEarly diagnosisSymptom onsetPathological findingsDiffuse large B-cell lymphomaCase of neurolymphomatosisDiagnosis of neurolymphomatosisYale Cancer CenterTertiary referral centerFDG-PET imagingPeripheral nervous systemB-cell lymphomaImaging gold standardSPSS version 27Painful polyneuropathyPainless polyneuropathySecondary neurolymphomatosisAutonomic neuropathyCranial neuropathiesMedian intervalReferral centerAutonomic nervesClinical suspicionFDG-PETCancer CenterImpact of radiotherapy delay following biopsy for patients with unresected glioblastoma.
Gao S, Jin L, Moliterno J, Corbin ZA, Bindra RS, Contessa JN, Yu JB, Park HS. Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma. Journal Of Neurosurgery 2022, 138: 610-620. PMID: 35907197, DOI: 10.3171/2022.5.jns212761.Peer-Reviewed Original ResearchConceptsWeeks of biopsyOverall survivalCox proportional hazards regression modelingProportional hazards regression modelingNational Cancer DatabaseInitiation of radiotherapyKaplan-Meier methodWorse overall survivalWilcoxon rank sum testEffects of confoundersRank sum testUnresected diseaseAdjuvant radiotherapyConcurrent chemotherapyMedian intervalMultivariable analysisRadiotherapy delayCancer DatabaseClinical dataBiopsyPatientsLate initiationAggressive natureRadiotherapyPotential association
2020
Primary membranous nephropathy in children and adolescents: a single-centre report from South Asia
Ramachandran R, Nayak S, Kumar V, Kumar A, Agrawal N, Bansal R, Tiewsoh K, Nada R, Rathi M, Kohli H. Primary membranous nephropathy in children and adolescents: a single-centre report from South Asia. Pediatric Nephrology 2020, 36: 1217-1226. PMID: 33108509, DOI: 10.1007/s00467-020-04798-8.Peer-Reviewed Original ResearchConceptsAssociated with clinical outcomesPartial remissionFollow-upImmunosuppressive therapyClinical outcomesMembranous nephropathyPatients treated with rituximabSymptom onset to presentationBiopsy-proven pMNSingle-centre reportsMedian follow-upFirst-line therapyPrimary membranous nephropathyMethodsThis prospective studyPercentage of patientsChildhood nephrotic syndromeMedian proteinuriaAnti-PLA2RMycophenolate mofetilMedian intervalMedian ageResistant diseaseClinical presentationNo significant differenceClinical behaviorSafety and Efficacy of Percutaneous Cholecystostomy for Emphysematous Cholecystitis
Imanzadeh A, Kokabi N, Pourjabbar S, Latich I, Pollak J, Kim H, Gunabushanam G. Safety and Efficacy of Percutaneous Cholecystostomy for Emphysematous Cholecystitis. Journal Of Clinical Imaging Science 2020, 10: 9. PMID: 32257585, PMCID: PMC7110106, DOI: 10.25259/jcis_145_2019.Peer-Reviewed Original ResearchPercutaneous cholecystostomyEmphysematous cholecystitisThirty-day survival ratesPoor operative candidatesPost-procedure dayPoor surgical candidatesTechnical success rateGallbladder wall thickeningMedical record searchInstitutional review board exemptionElective cholecystectomyHospitalization courseOperative candidatesCommon comorbiditiesMedian intervalSurgical candidatesUnrelated causesConsecutive patientsDefinitive treatmentIll patientsClinical outcomesIntramural gasRetrospective studyTube removalMean age
2019
Contemporary practice pattern of permanent pacing for conduction disorders in inferior ST‐elevation myocardial infarction
Misumida N, Ogunbayo G, Catanzaro J, Etaee F, Kim S, Abdel‐Latif A, Ziada K, Elayi C. Contemporary practice pattern of permanent pacing for conduction disorders in inferior ST‐elevation myocardial infarction. Clinical Cardiology 2019, 42: 728-734. PMID: 31173380, PMCID: PMC6671775, DOI: 10.1002/clc.23210.Peer-Reviewed Original ResearchConceptsST-elevation myocardial infarctionHigh-degree AV blockInferior ST-elevation myocardial infarctionSinoatrial node dysfunctionPermanent pacemaker implantationPacemaker implantationConduction disordersComplete AV blockAV blockContemporary practice patternsPermanent pacemakerMyocardial infarctionPractice patternsNational Inpatient Sample databaseSecond-degree AV blockAtrioventricular conduction disordersOptimal waiting periodMobitz type II second-degree AV blockInferior myocardial infarctionHospital mortalityMedian intervalPermanent pacingPrimary diagnosisPatientsSinoatrial node
2017
Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy
Rahimy E, Li FY, Hagberg L, Fuchs D, Robertson K, Meyerhoff DJ, Zetterberg H, Price RW, Gisslén M, Spudich S. Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy. The Journal Of Infectious Diseases 2017, 215: 1132-1140. PMID: 28368497, PMCID: PMC5426376, DOI: 10.1093/infdis/jix013.Peer-Reviewed Original ResearchConceptsPrimary HIV infectionCombination antiretroviral therapyHIV infectionNeurofilament light chainAntiretroviral therapyCreatinine levelsCerebrospinal fluidN-acetylaspartateAbnormal blood-brain barrier (BBB) permeabilityPrimary human immunodeficiency virus (HIV) infectionBlood-brain barrier disruptionHuman immunodeficiency virus (HIV) infectionBlood-brain barrier permeabilityNeuropsychological performanceImmunodeficiency virus infectionParietal gray matterYears of treatmentLongitudinal observational studyCART durationCART initiationMedian intervalNeuronal injuryAlbumin quotientNfL levelsCSF levelsOvarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature.
Gressel G, Buza N, Pal L. Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature. European Journal Of Gynaecological Oncology 2017, 38: 214-220. PMID: 29953783.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansHyperandrogenismHysterectomyMiddle AgedNeoadjuvant TherapyNeoplasm GradingOvarian NeoplasmsOvariectomyPostmenopauseRetrospective StudiesSalpingectomySertoli-Leydig Cell TumorConceptsSertoli-Leydig cell tumorOvarian Sertoli-Leydig cell tumorPresent patient populationDisease-free survivalSingle institution experienceTertiary care institutionTime of diagnosisOnset of menopauseRisk of recurrenceSeries of casesAdjuvant chemotherapyMedian followPostmenopausal bleedingPostmenopausal patientsMedian ageMedian intervalClinical presentationDefinitive managementPathological findingsRetrospective reviewInstitution experiencePatient populationTreatment modalitiesCell tumorsTumor grade
2012
Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR -mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.
Heon S, Nishino M, Goldberg S, Porter J, Sequist L, Jackman D, Johnson B. Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR -mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance. Journal Of Clinical Oncology 2012, 30: 7525-7525. DOI: 10.1200/jco.2012.30.15_suppl.7525.Peer-Reviewed Original ResearchNon-small cell lung cancerDrug-free intervalAdvanced non-small cell lung cancerEGFR-TKIEGFR mutationsMedian PFSMutant non-small cell lung cancerEGFR-mutant non-small cell lung cancerEGFR-mutant advanced non-small cell lung cancerSingle-agent gefitinibObjective tumor responseCell lung cancerSensitizing EGFR mutationsEGFR T790MNSCLC ptsRECIST 1.1Systemic regimensProspective trialMedian intervalRetrospective studyLung cancerTumor responseFree intervalPIK3CA mutationsRadiographic assessment
2007
Fate of the Remnant Pancreas after Resection of Noninvasive Intraductal Papillary Mucinous Neoplasm
White R, D’Angelica M, Katabi N, Tang L, Klimstra D, Fong Y, Brennan M, Allen P. Fate of the Remnant Pancreas after Resection of Noninvasive Intraductal Papillary Mucinous Neoplasm. Journal Of The American College Of Surgeons 2007, 204: 987-993. PMID: 17481526, DOI: 10.1016/j.jamcollsurg.2006.12.040.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmNoninvasive IPMNRisk of local recurrenceNoninvasive intraductal papillary mucinous neoplasmsLocal recurrencePapillary mucinous neoplasmPositive marginsMucinous neoplasmsDied of disease progressionLocal recurrence-free survivalMicroscopically positive marginsPancreatic resection databaseRecurrence-free survivalTime of resectionEvidence of diseaseIndefinite surveillanceNegative marginsMedian intervalRetrospective reviewRemnant pancreasOperative treatmentPancreatic remnantResectionPartial pancreatectomyDisease progression
2006
Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer
Murthy R, Oh Y, Tam A, Gupta S, Madoff D, Glisson B. Yttrium-90 microsphere treatment for liver dominant hepatic metastases from lung cancer. Journal Of Clinical Oncology 2006, 24: 17122-17122. DOI: 10.1200/jco.2006.24.18_suppl.17122.Peer-Reviewed Original ResearchHepatic metastasesSIR-SpheresLung cancerLiver metastasesSystemic therapyAdvanced liver metastasesLiver-dominant metastasesPrimary lung malignancyRegional hepatic therapyUnresectable hepatic metastasesColorectal liver metastasesLocal disease controlMetastatic lung cancerYttrium-90 Microsphere TreatmentMajority of patientsProgression of diseaseGr. 1Dominant metastasesStable diseaseVisceral arteriographyMedian doseSystemic chemotherapyArterial embolizationLine therapyMedian interval
1993
Urolithiasis in Children Following Augmentation Cystoplasty
Palmer L, Franco I, Kogan S, Reda E, Gill B, Levitt S. Urolithiasis in Children Following Augmentation Cystoplasty. Journal Of Urology 1993, 150: 726-729. PMID: 8326634, DOI: 10.1016/s0022-5347(17)35598-2.Peer-Reviewed Original ResearchConceptsAugmentation cystoplastyUrinary tract infectionSignificant risk factorsUpper tract calculiMajority of casesTract infectionsMedian intervalBladder calculiRisk factorsAbsorbable staplesCystoplastyLower tractYoung adultsIntestinal mucusAmmonium urateUrinary calculiChildrenCalculi compositionHypocitraturiaComplicationsSurgeryUrolithiasisInfectionTract
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply